Final Results of Phase 2 Clinical Trial Clarify Role of JAK2 Inhibitor in Combating Acute Graft-Versus-Host Disease
Final Results of Phase 2 Clinical Trial Clarify Role of JAK2 Inhibitor in Combating Acute Graft-Versus-Host Disease
Study led by Roswell Park’s Dr. Brian Betts answers longstanding question in stem cell transplantation
Details
More Products & Services
People
Kimberly Sweeney
Roswell Park Comprehensive Cancer Center
Vice President of Patient Experience
Sai Yendamuri
Roswell Park Comprehensive Cancer Center
Chief Strategy Officer; SVP of Business Development & Outreach; Chair of Thoracic Surgery
Shashi Lele
Roswell Park Comprehensive Cancer Center
Medical Director, International Patients
Sunita Panesar
Roswell Park Comprehensive Cancer Center
Vice President of Strategy, Business Development & Outreach
Description
HIGHLIGHTS:
- Study added pacritinib to standard sirolimus/tacrolimus regimen
- JAK2 inhibition + reducing Th1/Th17 cells does not improve GVHD prevention
- Results published in Blood, the leading hematology journal
- Study added pacritinib to standard sirolimus/tacrolimus regimen
- JAK2 inhibition + reducing Th1/Th17 cells does not improve GVHD prevention
- Results published in Blood, the leading hematology journal
Share
Recent Chats
Share via email
Future: handle WhatsApp here
Future: handle LinkedIn here
Future: handle Twitter here
SUBMENU HERE
Share via Chat
Copy Link
You've reached your free preview limit
Create an account to continue exploring
Currently viewing: International Medical Concierge Program
Preview limit reached
Continue exploring
You've reached your free preview limit
Unlock full access
Continue Exploring
Continue Exploring
Create an account to find in-depth information on thousands of companies, people and products in your industry
- Find the right companies and products ... fast
- Bookmark events, companies, people and products you are interested in
- Message company representatives directly
- Plan ahead for upcoming shows you are attending
Already have an account? Sign in
Free to use · No spam · Built for professionals